GKT137831: Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a potent, selective dual inhibitor of NADPH oxidase isoforms Nox1 and Nox4, with Ki values of 140 nM and 110 nM, respectively. It reduces reactive oxygen species (ROS) production, thereby attenuating downstream oxidative stress and pathological remodeling in both in vitro and in vivo models. GKT137831 modulates signaling pathways such as Akt/mTOR and NF-κB, impacting inflammation and fibrosis. At experimental concentrations of 0.1–20 μM and typical incubation periods of 24 hours, it demonstrates efficacy across models of pulmonary vascular remodeling, liver fibrosis, and diabetes-accelerated atherosclerosis. The product is available from APExBIO and has been validated in peer-reviewed studies, supporting its role in translational oxidative stress research (GKT137831 product page).

Biological Rationale

Reactive oxygen species (ROS) are chemically reactive molecules containing oxygen. They are generated in cells during normal metabolism but can accumulate to pathological levels in disease states. NADPH oxidase (Nox) enzymes, especially Nox1 and Nox4, are major sources of ROS in vascular and fibrotic tissues (Yang et al., 2025). Excessive ROS promotes cellular injury, inflammation, and fibrosis via activation of signaling pathways such as Akt/mTOR and NF-κB. Inhibiting Nox1 and Nox4 reduces ROS burden, providing a mechanism to investigate and modulate oxidative stress in experimental systems (see related article—this article extends the molecular context to preclinical applications).

Mechanism of Action of GKT137831

GKT137831 acts as a competitive inhibitor of Nox1 and Nox4, binding with Ki values of 140 nM and 110 nM, respectively. This dual inhibition blocks the transfer of electrons from NADPH to molecular oxygen, thereby decreasing ROS generation. Reduced ROS levels limit oxidative modification of cellular proteins, nucleic acids, and lipids. Downstream, this leads to suppression of Akt/mTOR and NF-κB signaling, which are implicated in cell proliferation, inflammation, and tissue remodeling. In vitro, GKT137831 significantly reduces hypoxia-induced hydrogen peroxide (H₂O₂) release from human pulmonary artery endothelial cells (HPAECs) and smooth muscle cells (HPASMCs). It also suppresses the expression of TGF-β1 (a key fibrotic mediator) and increases PPARγ (a regulator of metabolic and inflammatory responses).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 and Nox4 with Ki values of 140 nM (Nox1) and 110 nM (Nox4), as determined by enzymatic assays in cell-free systems (Yang et al., 2025).
• In vitro, GKT137831 reduces hypoxia-driven H₂O₂ production in HPAECs and HPASMCs by >60% at 10 μM over 24 hours (Yang et al., 2025, Table S2).
• Oral administration (30–60 mg/kg/day) in mice attenuates pulmonary vascular remodeling and right ventricular hypertrophy after chronic hypoxia exposure (Yang et al., 2025, Fig. 3).
• In liver fibrosis models, GKT137831 reduces collagen deposition and TGF-β1 expression at experimental doses (30 mg/kg/day, 4 weeks) (Yang et al., 2025).
• In diabetes-accelerated atherosclerosis mouse models, GKT137831 reduces aortic plaque burden and vascular inflammation (Yang et al., 2025).
• Clinical evaluation indicates safety and tolerability in human subjects (see APExBIO GKT137831 for details).

For in-depth benchmarking and use-case analysis, see this related article, which offers advanced workflows. This article expands upon those findings by detailing experimental boundaries and clinical translation.

Applications, Limits & Misconceptions

GKT137831 is widely used in preclinical research for:

• Dissecting the role of Nox1/Nox4 in oxidative stress and ROS-driven signaling.
• Modeling pulmonary hypertension, vascular remodeling, and right ventricular hypertrophy in murine models.
• Studying liver fibrosis, diabetes-accelerated atherosclerosis, and redox-modulated inflammation.
• Validating the impact of Nox inhibition on TGF-β1, PPARγ, and related markers.

GKT137831 is not a pan-NADPH oxidase inhibitor; it is highly selective for Nox1 and Nox4, with limited activity against other Nox isoforms. It does not directly scavenge ROS but acts upstream to prevent their generation. Its efficacy is dose- and context-dependent, with recommended concentrations ranging from 0.1 to 20 μM in vitro, and 30–60 mg/kg/day orally in mice. For practical integration strategies, refer to this article, which this piece extends by clarifying in vivo translation and experimental design limits.

Common Pitfalls or Misconceptions

• GKT137831 is ineffective against Nox2-driven ROS production (see Yang et al., 2025).
• It does not function as a direct antioxidant or ROS scavenger.
• Use in water-based solutions is limited by low solubility; DMSO or ethanol are preferred solvents.
• Long-term storage of GKT137831 solutions at room temperature leads to degradation; store at -20°C for optimal stability.
• Results from murine models may not fully extrapolate to human disease without further validation.

Workflow Integration & Parameters

GKT137831 (SKU B4763) is provided by APExBIO for research use. It is soluble at ≥39.5 mg/mL in DMSO and at ≥2.96 mg/mL in ethanol (with warming and sonication). It is insoluble in water. Recommended storage is at -20°C, and reconstituted solutions should not be stored long-term. Experimental concentrations typically range from 0.1–20 μM for cell assays with 24-hour incubation. In vivo, oral dosing of 30–60 mg/kg/day is standard for mice. Controls should include vehicle-only and/or positive Nox inhibition comparators. Key readouts include ROS quantification (e.g., H₂O₂ assays), pathway analysis (Akt/mTOR, NF-κB), and phenotype scoring (fibrosis, remodeling).

For scenario-driven troubleshooting and practical guidance, this article provides laboratory insights. Here, we extend the discussion to include translational and clinical considerations.

Conclusion & Outlook

GKT137831 is a validated, selective dual Nox1/Nox4 inhibitor for oxidative stress research, enabling precise modulation of ROS-dependent pathways. Its nanomolar potency, robust in vitro and in vivo efficacy, and expanding clinical evaluation support its use in translational workflows targeting vascular remodeling, fibrosis, and related pathologies. Future research may further elucidate its therapeutic potential and boundary conditions. For up-to-date information, consult the GKT137831 product page at APExBIO.